At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Abiraterone acetatedrug
Likely dose
Abiraterone acetate 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC) and Prior Therapy With Ketoconazole
In Brief
A Phase 2 clinical trial evaluating Abiraterone acetate for Prostate Cancer. Completed, enrolled 42 participants across 2 sites.
Detailed Summary
This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole. It is hypothesized that abiraterone will be active in patients who have experienced disease progression on ketoconazole
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsJohnson & Johnson, Cougar Biotechnology, Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartSep 2010
Primary CompletionJan 2013
Study CompletionMar 2016
TodayJul 2026
First PostedSep 10, 2010
Enrollment StartSep 10, 2010
Primary CompletionJan 4, 2013
Study CompletionMar 14, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.8 years ago
Interventions
Abiraterone acetatedrug
Abiraterone acetate 1000 mg by mouth per day